PACB PACIFIC BIOSCIENCES OF CALIFORNIA, INC.companySEC Filings & Insider Trading Activity 2026
Latest PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 25, 2026, a 10-Q quarterly report filed on November 6, 2025, an 8-K current report filed on March 6, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) (SEC CIK 1299130), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 5.02: Departure/Appointment of Directors or Principal Officers
- • Michele Farmer resigning as CAO effective March 21, 2026 — voluntary departure, no severance, no disagreements with company
- • CFO Jim Gibson absorbs principal accounting officer role with no additional compensation change
Item 7.01: Regulation FD Disclosure
- • Settlement with PGI ends patent litigation; PACB pays $8M in Q1 2026, then $5M/year in Q1 2027–2029 (total minimum $23M)
- • 2027 payment increases by $1M if 2026 revenue ≥$165M, another $1M if ≥$180M — creating a revenue-linked contingent liability up to $25M total
Item 7.01: Regulation FD Disclosure
- • Dr. Gibson appointed to a key role at Pacific Biosciences, announced via press release dated March 5, 2026
- • Leadership change potentially signals strategic or scientific direction shift — full terms in Exhibit 99.1
Item 5.02: Departure/Appointment of Directors or Principal Officers
- • Board expanded to 10 directors; Christopher Gibson, Ph.D. appointed Class I director effective March 3, 2026
- • Gibson assigned to Science and Technology Committee — signals focus on scientific/R&D credibility for PACB's genomics platform
Recent 8-K FilingsCurrent Reports
AI-powered analysis of PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $128.3M | $200.5M | $154.0M | $160.0M |
| Gross Profit | $49.0M | $52.8M | $37.3M | $45.8M |
| Operating Income | — | -$334.5M | -$474.3M | -$553.9M |
| Net Income | — | -$306.7M | -$309.9M | -$546.4M |
| Gross Margin | 38.2% | 26.3% | 24.2% | 28.6% |
| Op. Margin | — | -166.8% | -308.0% | -346.2% |
| Net Margin | — | -153.0% | -201.2% | -341.5% |
| Balance Sheet | ||||
| Total Assets | — | $1.7B | $1.3B | $784.1M |
| Equity | — | $701.3M | $506.6M | $5.3M |
| ROE | — | -43.7% | -61.2% | -10214.5% |
Source: XBRL financial data from PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Mar 6, 2026 | — | Analysis | — |
8-K | Mar 5, 2026 | — | Analysis | — |
10-K | Feb 25, 2026 | Dec 31, 2025 | — | |
8-K | Feb 12, 2026 | — | — | |
8-K | Feb 3, 2026 | — | — | |
8-K | Feb 2, 2026 | — | — | |
8-K | Jan 12, 2026 | — | — | |
10-Q | Nov 6, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 7, 2025 | Jun 30, 2025 | — | |
10-Q | May 12, 2025 | Mar 31, 2025 | — | |
10-K | Mar 17, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 12, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 9, 2024 | Jun 30, 2024 | — | |
10-Q | May 9, 2024 | Mar 31, 2024 | — | |
10-K | Feb 28, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 3, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 4, 2023 | Jun 30, 2023 | — | |
10-Q | May 4, 2023 | Mar 31, 2023 | — | |
10-K | Feb 28, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 8, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 8, 2022 | Jun 30, 2022 | — | |
10-Q | May 6, 2022 | Mar 31, 2022 | — | |
10-K | Feb 28, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 5, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 6, 2021 | Jun 30, 2021 | — |
Frequently Asked Questions
What are the latest PACB SEC filings in 2026?
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) has filed a 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 6, 2025, an 8-K current report on March 6, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did PACB file its most recent 10-K annual report?
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed its most recent 10-K annual report on February 25, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view PACB 10-Q quarterly reports?
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)'s most recent 10-Q quarterly report was filed on November 6, 2025. SignalX displays every PACB 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has PACB filed recently?
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)'s most recent 8-K was filed on March 6, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find PACB insider trading activity (Form 4)?
SignalX aggregates every PACB Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does PACB file with the SEC?
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new PACB filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB).
What is PACB's SEC CIK number?
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)'s SEC CIK (Central Index Key) number is 1299130. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1299130 to look up all PACB filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find PACB return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of PACIFIC BIOSCIENCES OF CALIFORNIA, INC. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 68+ filings.